RIPK1 and systemic inflammatory response syndrome: The study highlighted the clinical relevance of RIPK1 kinase inhibition in sepsis and revealed the possibility of targeting RIPK1 in the programmed necrosis pathway as a potential therapeutic target for SIRS and sepsis (Gupta et al., 2018).